For more than a decade, South Korea has been a pioneer in the use of robots to aid teaching. Now, the country will offer middle school classes in robotics.
Will COVID-19 treatment be Celltrion founder’s retirement legacy?
Results of phase 2 clinical trial of coronavirus antibody agent set to be unveiled |
Celltrion logo (Celltrion)
Late on the front of coronavirus vaccine development and procurement, South Korea is pinning hopes on one particular company to provide the much-needed relief in this dark, pandemic winter Celltrion.
The company is expected to announce in coming days results of its global clinical phase 2 trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59.
Celltrion’s media-friendly founder and chairman Seo Jung-jin has said plenty of times that its drug, if approved, would “put an end” to the country’s struggles with the deadly virus.